Comparing the current results to its competitors, Neurogene Inc reported Revenue decrease in the 1 quarter 2026 year on year by 0 %, slower than the combined decrease of the NGNE's competitors by -7.99 %, recorded in the same quarter.
Neurogene Inc 's Comment on Competition and Industry Peers
The competitive landscape includes Acadia, which has acquired worldwide rights to NNZ-2591, an investigational synthetic analogue of cyclo-glycyl-proline being developed for Rett syndrome and other neurodevelopmental syndromes. Trofinetide is also mentioned but is not considered directly competitive due to its distinct mechanism of action. Competitors generally possess greater financial, technical, and human resources, as well as more experience in drug discovery, development, regulatory approvals, and commercialization. Industry mergers, acquisitions, and partnerships may concentrate resources among fewer competitors, potentially enhancing their ability to obtain regulatory approvals and market acceptance. The development of a cure or more effective treatment by competitors could render the company's product candidate non-competitive or obsolete. The company maintains a Master Collaboration Agreement with The University of Edinburgh. Market exclusivity periods in the European Union may delay the entry of competitors' generic or biosimilar products.
November 19, 2024
Neurogene Reports Third Quarter 2024 Financial Results and Highlights Recent Updates In an era where the convergence of cutting-edge science and innovative business models is reshaping the landscape of biotechnology, Neurogene Inc. (Nasdaq: NGNE) stands at the forefront, dedicated to transforming the lives of patients afflicted with rare neurological diseases through pioneering genetic medicines. In its recent announcement regarding the financial results for the third quarter of 2024, Neurogene has showcased substantial progress both in clinical trials and its business trajectory, fostering optimism among stakeholders.As of this writing, shares of Neurogene Inc. are trading at $19.82, signifying a modest 0...
November 18, 2024
Neurogene Provides Update on NGN-401 Gene Therapy Clinical Trial for Rett Syndrome In a significant era for genetic medicine, Neurogene Inc. (Nasdaq: NGNE), a clinical-stage biotech company focused on addressing the needs of patients with rare neurological diseases, is making strides in its Phase 1/2 open-label clinical trial for NGN-401, a gene therapy targeting Rett syndrome. The recent update, which was made public on November 11, 2024, brought to light a new and concerning development: a treatment-related serious adverse event (SAE) that occurred in one of the trial participants. While the details surrounding this emerging event remain undisclosed, such occurrences underscore the complexities and inheren...
August 9, 2024
: Neurogene Inc., a clinical-stage biotechnology company focused on developing genetic therapies for rare neurological diseases, has made significant strides in its NGN-401 gene therapy program for Rett syndrome. Recent updates include financial results for the second quarter of 2024 and key milestones in clinical trials. With the company s innovative approaches recognized by regulatory bodies such as the FDA, Neurogene is positioning itself at the forefront of gene therapy advancements. This article outlines the latest developments regarding NGN-401, emphasizing its clinical trial progress, regulatory designations, and implications for patients with Rett syndrome.Neurogene Inc. (Nasdaq: NGNE), headquartered...
July 1, 2024
CSIMarket.com is pleased to feature Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company committed to developing life-changing genetic treatments for families and patients afflicted by rare neurological diseases. Neurogene has recently achieved several notable advancements, reflecting its growing influence in the realm of biotechnology and its steadfast dedication to pioneering treatments for rare diseases. Inclusion in the Russell 3000 Index In a significant financial milestone, Neurogene has been added to the Russell 3000 Index, effective as of July 1, 2024. The Russell 3000 Index, which is reconstituted annually, encompasses the 4,000 largest U.S. stocks, ranked by total market capitalization as of A...
May 12, 2024
Neurogene Inc. Reports Promising Financial Results and Progress in Genetic Medicine Development for Rare Neurological DiseasesIn a recent press release, Neurogene Inc., a clinical-stage company focused on providing groundbreaking genetic medicines for individuals and families affected by rare neurological diseases, has announced its first quarter financial results for 2024. Additionally, the company highlighted significant advancements in their NGN-401 Rett syndrome gene therapy program.Neurogene has displayed a remarkable progress in the NGN-401 Rett syndrome gene therapy program since the beginning of this year. One notable achievement is the successful dosing of the third patient in the trial. Furthermore...
April 23, 2024
Neurogene Inc., a clinical-stage genetic medicines company listed on Nasdaq (NGNE), has announced plans to present initial safety and tolerability data gained from its ongoing Phase 1/2 gene therapy clinical trial for people with Rett Syndrome. The company, which focuses on offering life-altering treatments for patients and families affected by rare neurological disorders, has confirmed that the data will be presented at the American Society for Gene and Cell Therapy (ASGCT) Annual Meeting.The particular gene therapy under trial, NGN-401, aims to target Rett Syndrome, a severe neurodevelopmental disorder predominantly affecting females. Children suffering from Rett Syndrome show regular early growth but sadl...
March 4, 2024
Expanding Horizons: Accelerated Enrollment and Promising Breakthroughs in Rett Syndrome Gene Therapy Clinical TrialNeurogene Inc., a pioneering clinical-stage company dedicated to ushering in transformative genetic medicines for individuals and families affected by rare neurological disorders, recently unveiled plans to expand its ongoing Phase 1/2 gene therapy clinical trial for NGN-401. This groundbreaking trial focuses on female pediatric patients grappling with Rett syndrome, a debilitating genetic disorder primarily affecting the nervous system. The company also aims to enhance the trial s enrollment process, enabling more rapid participation and assessment.Rett syndrome, although considered rare, is a ...
Voyager Therapeutics Inc. is a biopharmaceutical company that focuses on the development of gene therapies to treat severe neurological diseases. Their business model revolves around research, development, and commercialization of innovative treatments using viral gene therapy technology.
Corcept Therapeutics Inc operates using a business model that focuses primarily on the research, development, and commercialization of pharmaceutical products. The company aims to discover and develop medications for conditions related to cortisol dysregulation, with a specific focus on Cushing's syndrome and psychiatric disorders. Additionally, Corcept Therapeutics Inc aims to ensure the successful commercialization of their products through collaborations and partnerships with other organizations to reach a wider market.
Centessa Pharmaceuticals Plc operates as a biopharmaceutical company that focuses on the discovery and development of innovative medicines. Their business model centers around leveraging a decentralized approach, with multiple subsidiary companies working autonomously to accelerate the research and development of potential therapeutics across various disease areas. By bringing together diverse expertise and resources, Centessa aims to efficiently advance breakthrough therapies and deliver impactful solutions to patients in need.
Audentes Therapeutics Inc is a biotechnology company focused on developing and commercializing innovative gene therapies for serious rare diseases. Their business model revolves around conducting extensive research and development to design and produce these gene therapies. They then collaborate with healthcare providers and regulatory bodies to gain necessary approvals and commercialize their therapies, aiming to provide effective treatments for patients suffering from rare diseases.
Sources:
Neurogene Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Neurogene Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
